IGF2BP2 and lung carcinoma: In lung cancer, Shen and colleagues demonstrated that IGF2BP2 permeates ECs in the microenvironmental via lung adenocarcinoma (LUAD) cell-derived exosomes, subsequently mediating the m6A modification of FLT4 to improve its stability and expression.